ESPITE an extensive knowledge of cardiac cation channels since the advent of patch-clamp techniques in the early 1980s, our understanding of anion channels had lagged far behind until the demonstration in 1989 that the isoproterenol (Iso)-induced, background currents of guinea pig ventricular myocytes were Cl-selective.1-3) Successful single-channel recordings were subsequently made from guinea pig ventricular myocytes in 1990, indicating an outwardly-rectifying channel of relatively low conductance (13 pS at positive membrane potentials) in cell-attached patches from cells exposed to adrenaline.4) These channels show many similarities to epithelial cystic fibrosis transmembrane conductance regulator (CFTR) Cl-channels in terms of regulation by cyclic AMP, conductance and ion selectivity.5) Indeed, cardiac tissues express mRNA homologous to human CFTR, suggesting that the cardiac cyclic AMP- der certain pathophysiological conditions, including coronary vasospasm, cardiac ischemia and myocardial infarction. Angiotensin-II (A-II) is an octapeptide hormone which, like ET-1, has a potent positive inotropic action and promotes myocardial hypertrophy after acute myocardial infarction62-64) and in hypertensive rat models.65,66) Two subtypes of receptor for A-II have been cloned, AT1 and AT2, both of which are members of the GTP-binding protein-coupled family, and the myocardium is enriched in receptors for A-II.67) The pathophysiological roles of the renin-angiotensin system (RAS) have been highlighted in recent years by large-scale clinical trials in which angiotensin-converting enzyme (ACE) inhibitors have been shown to be highly effective in reducing cardiovascular morbidity and mortality. Myocardial levels of A-II, the principal effector of the RAS, are known to be increased without an increase in plasma renin levels under certain pathophysiological conditions and it would appear that A-II may, like ET-1, act as an autocrine or paracrine hormone in the heart.67,72) More interestingly, both ET-1 and A-II have been shown to couple to phosphoinositide (PI) hydrolysis, protein kinase C activation, and arachidonic acid metabolism in the myocardium which have been suggested to contribute to the hypertrophic and positive inotropic responses to the hormones.58-60,72) The inhibitory effects of these peptide hormones on the CFTR Cl-channel current were seen in whole-cell patch-clamp experiments using pipette solutions in which the free Ca2+ concentration was tightly buffered to very low levels (<1nM). Since the activities of the Ca2+-dependent phospholipases PLC and PLA2 would be extremely reduced, it is unlikely that PI hydrolysis or arachidonic acid metabolism contributed to the inhibitory action of either ET-1 or A-II. Rather, our data would suggest a novel pathway for the action of these hormones in the myocardium. The inhibitory effect of both ET-1 and A-II could be occluded by pretreatment of the myocytes with PTX for at least one hour, suggesting the involvement of Gi or Go GTP-binding proteins.57,58) Since the peptide hormones could inhibit the current induced by forskolin, but not by intracellular administration of cyclic AMP via the pipette, the site of action would seem to be distal to adenylate cyclase activation but proximal to cyclic AMP-dependent activation of the channel by protein kinase A (Figure 1 ). Radioimmunoassay of tissue cyclic AMP levels indicates that ET-1 and A-II act by reducing the intracellular cyclic AMP concentration,57,58) which is strongly reminiscent of the action of muscarinic agonists on the CFTR Cl-current.
In conclusion, it is suggested that ET-1 and A-II may act as autocrine/ paracrine hormones by modulating responses to catecholamines in the heart. Inhibition of the CFTR Cl-conductance will counteract the catecholamine-induced shortening of the APD and this inhibitory action of the peptide hormones 
